Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia

M. D. Bronstein; M. Knoepfelmacher; B. Liberman; R. Marino; O. A. Germek; A. V. Schally

doi:10.1055/s-2007-1011796

Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia

M. D. Bronstein, M. Knoepfelmacher, B. Liberman, R. Marino, O. A. Germek, A. V. Schally

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

The effect of somatostatin (SRIF: 10 μg/min during 120 min) on serum prolactin (PRL) levels was studied in eleven patients with hyperprolactinemia of varying causes: 2 patients with acromegaly; 2 with primary hypothyroidism; 4 with prolactinoma and 3 with drug (sulpiride) induced hyperprolactinemia. During SRIF infusion, no significant change in PRL levels was observed in any of the 4 groups studied except in one female patient with a prolactinoma. The biological activity of SRIF was demonstrated by the significant inhibition (P < 0.05) of insulin levels seen in all 11 patients (52% fall in relation to basal) without simultaneous modification of glycemia. These data suggest that SRIF does not decrease PRL secretion in most patients with hyperprolactinemia.

Original language	English (US)
Pages (from-to)	271-274
Number of pages	4
Journal	Hormone and Metabolic Research
Volume	19
Issue number	6
DOIs	https://doi.org/10.1055/s-2007-1011796
State	Published - Jan 1 1987
Externally published	Yes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry
Endocrinology
Clinical Biochemistry
Biochemistry, medical

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1055/s-2007-1011796

Cite this

@article{290a918b9ce04ceb9e21c944c74e5003,

title = "Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia",

abstract = "The effect of somatostatin (SRIF: 10 μg/min during 120 min) on serum prolactin (PRL) levels was studied in eleven patients with hyperprolactinemia of varying causes: 2 patients with acromegaly; 2 with primary hypothyroidism; 4 with prolactinoma and 3 with drug (sulpiride) induced hyperprolactinemia. During SRIF infusion, no significant change in PRL levels was observed in any of the 4 groups studied except in one female patient with a prolactinoma. The biological activity of SRIF was demonstrated by the significant inhibition (P < 0.05) of insulin levels seen in all 11 patients (52% fall in relation to basal) without simultaneous modification of glycemia. These data suggest that SRIF does not decrease PRL secretion in most patients with hyperprolactinemia.",

author = "Bronstein, {M. D.} and M. Knoepfelmacher and B. Liberman and R. Marino and Germek, {O. A.} and Schally, {A. V.}",

year = "1987",

month = jan,

day = "1",

doi = "10.1055/s-2007-1011796",

language = "English (US)",

volume = "19",

pages = "271--274",

journal = "Hormone and Metabolic Research",

issn = "0018-5043",

publisher = "Georg Thieme Verlag",

number = "6",

}

TY - JOUR

T1 - Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia

AU - Bronstein, M. D.

AU - Knoepfelmacher, M.

AU - Liberman, B.

AU - Marino, R.

AU - Germek, O. A.

AU - Schally, A. V.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - The effect of somatostatin (SRIF: 10 μg/min during 120 min) on serum prolactin (PRL) levels was studied in eleven patients with hyperprolactinemia of varying causes: 2 patients with acromegaly; 2 with primary hypothyroidism; 4 with prolactinoma and 3 with drug (sulpiride) induced hyperprolactinemia. During SRIF infusion, no significant change in PRL levels was observed in any of the 4 groups studied except in one female patient with a prolactinoma. The biological activity of SRIF was demonstrated by the significant inhibition (P < 0.05) of insulin levels seen in all 11 patients (52% fall in relation to basal) without simultaneous modification of glycemia. These data suggest that SRIF does not decrease PRL secretion in most patients with hyperprolactinemia.

AB - The effect of somatostatin (SRIF: 10 μg/min during 120 min) on serum prolactin (PRL) levels was studied in eleven patients with hyperprolactinemia of varying causes: 2 patients with acromegaly; 2 with primary hypothyroidism; 4 with prolactinoma and 3 with drug (sulpiride) induced hyperprolactinemia. During SRIF infusion, no significant change in PRL levels was observed in any of the 4 groups studied except in one female patient with a prolactinoma. The biological activity of SRIF was demonstrated by the significant inhibition (P < 0.05) of insulin levels seen in all 11 patients (52% fall in relation to basal) without simultaneous modification of glycemia. These data suggest that SRIF does not decrease PRL secretion in most patients with hyperprolactinemia.

UR - http://www.scopus.com/inward/record.url?scp=0023182942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023182942&partnerID=8YFLogxK

U2 - 10.1055/s-2007-1011796

DO - 10.1055/s-2007-1011796

M3 - Article

C2 - 2887502

AN - SCOPUS:0023182942

VL - 19

SP - 271

EP - 274

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 6

ER -

Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this